Saponin adjuvant compositions and methods relating thereto
View Patent ↗An adjuvant composition which comprises an anionic macromolecule component particularly an ionic polysaccharide such as DEAE-dextran, and a saponin component, particularly an immunostimulating complex component. Immunogenic compositions comprising an immunogen and this adjuvant composition are also disclosed together with methods of use thereof.
1. A liquid aqueous adjuvant composition consisting essentially of an ionic polysaccharide component and immunostimulating complex, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.
2. The adjuvant composition of claim 1 , wherein an ionic polysaccharide is an ionic dextran.
3. The adjuvant composition of claim 2 , wherein an ionic dextran is DEAE-dextran or QAE-dextran.
4. The adjuvant composition of claim 1 , wherein the immunostimulating complex is a protein-free immunostimulating complex.
5. The adjuvant composition of claim 1 , wherein the immunostimulating complex comprises cholesterol, phosphatidyl choline, and Quil A.
6. The adjuvant composition of claim 1 , wherein the mass ratio is about 125.
7. The adjuvant composition of claim 1 , comprising about 10 mg of the ionic polysaccharide and about 80 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
8. The adjuvant composition of claim 1 , comprising about 100 mg of the ionic polysaccharide and about 800 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
9. A liquid aqueous immunogenic composition comprising an immunogen and the adjuvant composition of claim 1 .
10. The immunogenic composition of claim 9 , wherein said immunogen comprises LHRH.
11. The immunogenic composition of claim 10 , wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.
12. The immunogenic composition of claim 11 , comprising from about 5 to about 500 μg of LHRH-diphtheria toxoid conjugate, from about 5 to about 500 mg of the ionic polysaccharide, and from about 40 to about 4000 μg of the immunostimulating complex.
13. A liquid aqueous vaccine comprising (i) an immunogen, (ii) an adjuvant composition consisting essentially of an ionic polysaccharide component and immunostimulating complex and (iii) one or more pharmaceutically acceptable carriers wherein:
a) said immunogen is LHRH; or
b) the mass ratio of the ionic polysaccharide component to the immunostimulating complex component is in the range of about 100 to about 140.
14. A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the vaccine of claim 13 .
15. The vaccine of claim 13 , wherein the mass ratio of the ionic polysaccharide component to the immunostimulating complex component is in the range of about 100 to about 140.
16. A liquid aqueous adjuvant composition comprising an ionic polysaccharide component and immunostimulating complex, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.
17. The adjuvant composition of claim 16 , wherein an ionic dextran is DEAE-dextran or QAE-dextran.
18. The adjuvant composition of claim 16 , wherein the immunostimulating complex comprises cholesterol, phosphatidyl choline, and Quil A.
19. A liquid aqueous immunogenic composition comprising an immunogen and the adjuvant composition of claim 16 .
20. A liquid aqueous vaccine comprising (i) one or more immunogens, (ii) an adjuvant comprising an ionic polysaccharide component and immunostimulating complex, and (iii) one or more pharmaceutically acceptable carriers wherein:
a) said immunogen is LHRH; or
b) the mass ratio of the ionic polysaccharide component to the immunostimulating complex component is in the range of about 100 to about 140.
21. A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the vaccine of claim 20 .
22. A liquid aqueous adjuvant composition consisting essentially of an ionic polysaccharide component and immunostimulating complex, wherein the immunostimulating complex is a cage-like structure, and wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.
23. The immunogenic composition of claim 9 , wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is about 125.
24. The immunogenic composition of claim 9 , comprising about 100 mg of the ionic polysaccharide and about 800 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
25. The vaccine of claim 13 , wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.
26. The vaccine of claim 25 , wherein the mass ratio is about 125.
27. The vaccine of claim 13 , comprising about 100 mg of the ionic polysaccharide and about 800 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
28. The vaccine of claim 20 , wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.
29. The vaccine of claim 28 , wherein the mass ratio is about 125.
30. The vaccine of claim 20 , comprising about 100 mg of the ionic polysaccharide and about 800 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.
31. A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the vaccine of claim 20 .
32. The adjuvant composition of claim 3 , wherein the ionic dextran is DEAE-dextran, and wherein said composition is less reactogenic than a liquid adjuvant composition consisting essentially of DEAE Dextran.
33. The immunogenic composition of claim 9 , wherein the ionic polysaccharide component is DEAE-dextran, and wherein said composition is less reactogenic than a liquid immunogenic composition having an adjuvant component consisting essentially of DEAE Dextran.
34. A liquid vaccine composition of claim 13 , wherein the ionic polysaccharide component is DEAE-dextran, and wherein said composition is less reactogenic than a liquid immunogenic composition having an adjuvant component consisting essentially of DEAE Dextran.